Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Macrogenics (MGNX) Long-Term Investments (2016 - 2025)

Macrogenics (MGNX) has disclosed Long-Term Investments for 10 consecutive years, with $132.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Long-Term Investments rose 605.85% to $132.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $132.7 million, a 605.85% increase, with the full-year FY2025 number at $132.7 million, up 605.85% from a year prior.
  • Long-Term Investments was $132.7 million for Q4 2025 at Macrogenics, up from $66.3 million in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $166.5 million in Q3 2023 to a low of $8.6 million in Q1 2025.
  • A 5-year average of $84.7 million and a median of $106.1 million in 2021 define the central range for Long-Term Investments.
  • Biggest YoY gain for Long-Term Investments was 605.85% in 2025; the steepest drop was 91.75% in 2025.
  • Macrogenics' Long-Term Investments stood at $120.1 million in 2021, then crashed by 62.11% to $45.5 million in 2022, then skyrocketed by 183.08% to $128.8 million in 2023, then plummeted by 85.4% to $18.8 million in 2024, then skyrocketed by 605.85% to $132.7 million in 2025.
  • Per Business Quant, the three most recent readings for MGNX's Long-Term Investments are $132.7 million (Q4 2025), $66.3 million (Q3 2025), and $45.8 million (Q2 2025).